Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life by P. B. Jeppesen, P. Lund, I. B. Gottschalck, H. B. Nielsen, J. J. Holst, J. Mortensen, S. S. Poulsen, B. Quistorff, P. B. Mortensen

“…The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discontinuation of GLP-2 treatment. …”
Get full text